Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
about
Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndromeChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewUse of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgeryDabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.Study on Impact of Clinical Pharmacist's Interventions in the Optimal Use of Oral Anticoagulants in Stroke Patients.New potential therapies for the treatment of antiphospholipid syndrome.Stroke prevention treatment of patients with atrial fibrillation: old and new.Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal.Use of novel oral anticoagulant agents in venous thromboembolism.Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration.Paradoxical Procoagulant Effect of Early Doses of Warfarin: Possible Role of Non-Vitamin K Oral Anticoagulant in Patients with Atrial Fibrillation-Related Stroke.Reversible binding and quantification of heparin and chondroitin sulfate in water using redox-stable biferrocenylene SAMs.A model-based algorithm for the monitoring of long-term anticoagulation therapy.Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography.
P2860
Q24185813-4561B55F-A43A-4642-9D3E-3DDF6D28B061Q26765949-69B96167-EC42-499B-A5C5-95AC1F8E0EF2Q34099930-29910E47-7EF8-42CA-809D-19F06B7C1682Q35662599-FF69B74B-B39B-45BA-943E-3BDC2FFC4402Q36548878-F8AECE2F-7454-4D52-9770-F2128C004363Q37034722-371644CD-B3DC-4C9F-B7E6-CDB933CE35FFQ37481227-16C03720-7FF2-487D-B235-3A234E73AB22Q37810505-4186DAAE-EFAB-430F-BEEB-32C60E258AFBQ38266460-9CD81E04-3446-4222-95BF-FAB4BF836C9AQ38661819-ED1D6376-A145-4D47-8D33-53ABCC66772AQ38998384-94682299-F268-4CEF-AE92-A6C3711D0034Q41903969-C4EF3E86-2D18-4300-B09A-02E356B48CBAQ42567591-3FA50ACD-6D96-4844-B120-07F3AB296C66Q45778234-08AD0B2C-6F5C-4DC3-BEBD-D3691055F757Q46470678-D8A80DC0-BDEF-4D4B-A406-A984A201B7DEQ51039938-2E4DDE79-1CB7-401E-8E69-100D9D3C6D61Q53150077-D5DEA135-25C0-4A2B-A812-64249AA1C65C
P2860
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@ast
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@en
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@nl
type
label
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@ast
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@en
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@nl
prefLabel
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@ast
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@en
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@nl
P2860
P1476
Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects
@en
P2093
M D Freedman
P2860
P304
P356
10.1002/J.1552-4604.1992.TB03827.X
P407
P577
1992-03-01T00:00:00Z